The Pennant Group (NASDAQ:PNTG - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.22 per share and revenue of $201.40 million for the quarter.
The Pennant Group Stock Performance
NASDAQ:PNTG traded up $1.27 during midday trading on Friday, reaching $26.69. The stock had a trading volume of 167,163 shares, compared to its average volume of 225,108. The Pennant Group has a 12-month low of $20.78 and a 12-month high of $37.13. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 0.58. The firm has a fifty day simple moving average of $24.66 and a two-hundred day simple moving average of $27.54. The stock has a market cap of $926.73 million, a P/E ratio of 39.25, a P/E/G ratio of 2.24 and a beta of 1.56.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on the company. Stephens restated an "overweight" rating and set a $38.00 price objective on shares of The Pennant Group in a research report on Wednesday, April 2nd. Truist Financial cut their price objective on The Pennant Group from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.80.
Get Our Latest Research Report on PNTG
About The Pennant Group
(
Get Free Report)
The Pennant Group, Inc provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families.
Read More
Before you consider The Pennant Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and The Pennant Group wasn't on the list.
While The Pennant Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
